VF
AVBP icon

Virtu Financial’s ArriVent BioPharma AVBP Stock Holding History

Virtu Financial’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,300
Closed -$227K – 2400
2025
Q4 		$227K Buy
+11,300
New +$235K 0.01% 968
2025
Q3 		– Sell
-12,530
Closed -$273K – 2182
2025
Q2 		$273K Buy
+12,530
New +$260K 0.01% 788

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Virtu Financial's AVBP Position: Q1 2026 in Review

Virtu Financial sold out of ArriVent BioPharma (AVBP) in Q1 2026, closing a stake of 11,300 shares — an estimated $227K sold.

Virtu Financial first reported a position in AVBP in Q2 2025 and held it in 2 quarters. The position peaked at $273K in Q2 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Virtu Financial reported no remaining ArriVent BioPharma position as of Q1 2026 after selling out during the quarter.
  • Virtu Financial sold 11,300 ArriVent BioPharma shares in Q1 2026, an estimated $227K.
  • Virtu Financial first reported a position in ArriVent BioPharma in Q2 2025 and held it in 2 quarters.
  • Virtu Financial's ArriVent BioPharma position peaked at $273K in Q2 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.